Pulse Biosciences Files 8-K for Financials and Exhibits
Ticker: PLSE · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, routine-filing
TL;DR
Pulse Biosciences filed an 8-K for financials, nothing major to see here.
AI Summary
On January 21, 2025, Pulse Biosciences, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Miami, Florida.
Why It Matters
This filing indicates routine reporting of financial statements and exhibits, suggesting no immediate major corporate actions or significant business developments to report at this time.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, indicating no immediate material events or changes.
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- January 21, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- Miami, Florida (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Pulse Biosciences, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is January 21, 2025.
In which state is Pulse Biosciences, Inc. incorporated?
Pulse Biosciences, Inc. is incorporated in Delaware.
What is the address of Pulse Biosciences, Inc.'s principal executive offices?
The principal executive offices are located at 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.
Does this filing report any specific material events or other significant business updates?
Based on the provided text, this filing primarily concerns financial statements and exhibits and does not detail specific material events or other significant business updates.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-23 16:39:51
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20250121_8k.htm (8-K) — 30KB
- ex_767749.htm (EX-99.1) — 15KB
- 0001437749-25-001727.txt ( ) — 183KB
- plse-20250121.xsd (EX-101.SCH) — 3KB
- plse-20250121_def.xml (EX-101.DEF) — 12KB
- plse-20250121_lab.xml (EX-101.LAB) — 15KB
- plse-20250121_pre.xml (EX-101.PRE) — 12KB
- plse20250121_8k_htm.xml (XML) — 3KB
01
ITEM 8.01 OTHER EVENTS. On January 21, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing late-breaking data from the Company's first-in-human feasibility study of its Nanosecond PFA 360 Cardiac Catheter System. To date, 77 patients have been treated by six investigators in the study. The initial cohort of the first 30 patients treated have been evaluated by remapping completed at approximately three months post ablation procedure. Initial cohort study results include: All (100%) lesions were acutely successful with conduction block Success rate of pulmonary vein isolation (PVI) at ~3 months was 92.4% (109/118) Total PVI ablation time was 11.6 4.5 minutes Total procedure and fluoroscopy times were 88.3 30.1 and 6.9 2.4 minutes, respectively Left atrial dwell time was 29.6 15.3 minutes 1 Primary SAE (cardiac perforation) and 2 AEs including vertigo (n=1; managed conservatively) and creatinine elevation (n=1; treated with IV saline), with all AEs resolved without sequelae A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit Number Description 99.1 Press Release of Pulse Biosciences, Inc. dated January 21, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: January 23, 2025 By: /s/ Paul A. LaViolette Paul A. LaViolette Chief Executive Officer